Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(60.0%)
Phase 1
2(40.0%)
5Total
Early Phase 1(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07468708Early Phase 1Recruiting

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Role: lead

NCT07542379Early Phase 1Not Yet Recruiting

The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

Role: lead

NCT07459283Early Phase 1Not Yet Recruiting

The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

Role: lead

NCT06499350Phase 1Recruiting

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Role: lead

NCT06231550Phase 1Completed

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

Role: lead

All 5 trials loaded